CENTRAL MEDICAL SERVICES SOCIETY

(An Autonomous Body under Ministry of Health & Family Welfare, Govt. of India)

2nd Floor, Vishwa Yuvak Kendra, Teen Murti Marg,

Chanakyapuri, New Delhi-110021.

Date: 19.10.2026

Minutes of the Pre-Bid Meeting held on 01.10.2026 at 11:00 AM regarding Tender No. CMSS/PROC/2026-27/NACO/036 dated 25.09.2026 (GeM Bid No: GEM/2026/B/8082520) for the Procurement of HIV (Rapid) Test Kit-2 and Kit-3 for the National AIDS Control Organization (NACO)

Pre-bid queries raised by the bidder and Clarifications / Amendments by CMSS:

Sr. No.	Tender Clause No. & Page No.	As per Tender	Bidder's Query	Clarifications / Amendments
1.	SECTION VI TECHNICAL SPECIFICATIONS AND QUALITY ASSURANCE & Page No. 74	All the Principles may be included in the specifications as acceptable for the tendered kit, while ensuring that at least two of three selected kits are able to differentiate between HIV 1 and HIV 2.	Could you please confirm whether the requirement for HIV-1 and HIV-2 differentiation is applicable to the all types of kits, as in bid specification (page no.74) it has mentioned that "*at least two of the three selected kits should have the capability to differentiate between HIV-1 and HIV-2, irrespective of the testing principle used.*"	**Clarified as:** Refer Corrigendum-1.
2.	NA	NA	**GeM Uploading Files & Space Limitations:** Due to strict file size and count constraints on the GeM portal, uploading all comprehensive documentation becomes challenging. Kindly permit merging supporting documents or accepting supplementary **physical/offline** submissions where portal space is restricted.	**Clarified as:** As per the tender document, the bidder is requested to submit the bid and requisite documents online through the GeM portal.
3.	SECTION VI TECHNICAL SPECIFICATIONS AND QUALITY ASSURANCE & Page No. 73	Technical Specifications of HIV Test Kit 1, 2 & 3	Kindly keep all technical specifications aligned with Agenda 1, specifically for the detection of antibodies against HIV using any of the following principles: • Dot Immuno Assay • Immunochromatography (Lateral Flow) • Immuno-concentration (Flow Through) We are requesting you to please consider as Immunochromatography (Lateral Flow), mandatory principle this is one of the **primary technical principles used in Rapid Diagnostic Test (RDT) kits mandated** by the **National AIDS Control Organization (NACO) in India for point-of-care HIV screening.**	**Clarified as:** Refer Corrigendum-1.
4.			**Schedule 1** **Type of Test Kit**	**Clarified as:** As per Buyer-Uploaded ATC document

CENTRAL MEDICAL SERVICES SOCIETY ★ Vishwa Yuvak Kendra, Chanakyapuri New Delhi - 21 ★ MOHFW, Govt. of India ★

			HIV1 & HIV2 Antibodies Detection Rapid Test Kit, Hepatitis C Virus (HCV) Total Antibodies Detection Rapid Test Kit Please clarify this is HIV 1 & 2 Rapid Test or HCV Rapid Test and which one to quote. Since on Gem while participating in the bid HIV is not able to participate.	
5.	SECTION VI TECHNICAL SPECIFICATIONS AND QUALITY ASSURANCE & Page No. 73 Point No. 3	HIV test kit should have either of the following principles: a) Dot Immuno Assay b) Immunochromatography (lateral flow) c) Immuno-concentration (flow through)	**Schedule 1** **Testing Method** Lateral Flow (Immunochromatography) Request you to please clarify which principal bidder should consider to quote. Since in GeM tender it is mentioned Lateral Flow and in "Buyer Added Bid Specific Terms and Conditions" at Page 73, point No. 3 - principles mentioned - Dot Immunoassay Principle/Immunochromatography (Lateral Flow)/ Immunoconcentration (Flowthrough)	**Clarified as:** Refer Corrigendum-1.
6.			**Schedule 1** **Quantity** As per GeM – 9,14,650 packets As per tender document -9,14,650 Test Please clarify the mentioned quantity is in Packet or Test	**Clarified as:** As per Buyer-Uploaded ATC document
7.			**Schedule 1** **Pack Size** **As per GeM- 10 Test, 50 Test** Please clarify the pack size since this will have impact on price to quote.	**Clarified as:** As per Buyer-Uploaded ATC document
8.			**Schedule 2** **Type of Test Kit** HIV1 & HIV2 Antibodies Detection Rapid Test Kit, Hepatitis B Surface Antigen (HBsAg) Rapid Test Kit Please clarify this is HIV 1 & 2 Rapid Test or HCV Rapid Test and which one to quote. Since on Gem while participating in the bid HBsAg is been fetched and not the HIV.	**Clarified as:** Refer Corrigendum-1.
9.	SECTION VI TECHNICAL SPECIFICATIONS AND QUALITY ASSURANCE & Page No. 73		**Schedule 2** **Testing Method** As per GeM - Flow-Through Through (Immunoconcentration), Lateral Flow (Immunochromatography)Whereas as per tender document the principal mentioned - Dot Immunoassay Principle	**Clarified as:** Refer Corrigendum-1.



			/Immunochromatography (Lateral Flow)/Immunoconcentration (Flowthrough) Request you to please clarify which principal bidder should consider to quote. Since in GeM tender it is mentioned Flow-Through (Immunoconcentration), Lateral Flow (Immunochromatography) and in "Buyer Added Bid Specific Terms and Conditions" at Page73, point No. 3 - principles mentioned - Dot Immunoassay Principle/ Immunochromatography (Lateral Flow)/Immunoconcentration (Flowthrough)	
10.			**Schedule 2** **Quantity** As per GeM – 9,14,650 packets As per tender document -9,14,650 Test Please clarify the mentioned quantity is in Packet or Test	**Clarified as:** As per Buyer-Uploaded ATC document
11.			**Schedule 2** **Pack Size** **As per GeM- 10 Test, 50 Test** Please clarify the pack size since this will have impact on price to quote.	**Clarified as:** As per Buyer-Uploaded ATC document
12.	SECTION III: BID DATA SHEET (BDS) & Page No. 53 ITB 9.2.1.3 Para 6 e)	Certificate of Annual Production Capacity	Request you to please accept CA certified Annual Production Capacity certificate. Since as per MDR-2017 (letter from CDSCO attached), which states, Capacity & Quality certificates are presently not specified under the provisions of Medical Device Rules 2017.	**Clarified as:** As per Section IV – Qualification Criteria, Clause (h), of the Buyer-Uploaded ATC document
13.	SECTION II: INSTRUCTIONS TO BIDDERS (ITB) & Page No. 28 Para 5 i.	Certificate of Analysis of one batch of the quoted product should be submitted. Latest version of IP (2022) shall be referred.	Request you to please amend it as "Certificate of Analysis of one batch of the quoted product should be submitted". Since the COA as per Latest version of IP (2022) is applicable for pharmaceutical products.	**Clarified as:** Refer Corrigendum-1.
14.	SECTION V SCHEDULE OF REQUIREMENTS & Page No. 58		Inspection Methodology – PDI/Non-PDI Request you to please clarify that the consignments are to be dispatched after PDI or without PDI.	**Clarified as:** As per Section VIII - General Conditions of Contract (GCC), Clause GCC 7.1.7, of the Buyer-Uploaded ATC document
15.	SECTION VI TECHNICAL SPECIFICATIONS AND QUALITY ASSURANCE & Page No. 73 Point No. 3	HIV test kit should have either of the following principles: a) Dot Immuno Assay b) Immunochromatography (lateral flow)	Schedule mentions Dot Immunoassay / Immuno-concentration, whereas detailed specifications page no -73 point no -3 appear to describe Lateral Flow/Immunochromatography. Further they have also mention that all the	**Clarified as:** Refer Corrigendum-1.



		c) Immuno-concentration (flow through)	principal are accepted page no 74 (Important note) Since the detailed specification allows optional assay principles, the Schedule may kindly be clarified to permit both the specified principles and the optional principles, **including Lateral Flow/Immunochromatography,** subject to compliance with all stipulated performance, sensitivity, specificity, regulatory and technical requirements. This will maintain consistency between the Schedule and detailed specification and avoid ambiguity during technical evaluation.	
16.	SECTION VI TECHNICAL SPECIFICATIONS AND QUALITY ASSURANCE & Page No. 73 Point No. 9. b.	The assay component should include HIV-1 positive & negative controls, sufficient for conducting 20% of the test (10% negative & 10% positive controls)	The assay component should include HIV-1 positive & negative controls, sufficient for conducting 20% of the test (10% negative & 10% positive controls). The controls should be provide separately along with the kit if not the part of the kit **Technical Justification:** Negative and positive controls are essential for proper assay validation; however, due to specific storage requirement and the risk of contamination when packed with the kit components, we propose to provide the controls as separate components along with the kit. This arrangement ensures better stability, safe handling, and reliable performance of the controls without compromising the intended use of the assay.	**Clarified as:** No Change.
17.	SECTION VI TECHNICAL SPECIFICATIONS AND QUALITY ASSURANCE & Page No. 73 Point No. 3	HIV test kit should have either of the following principles: a) Dot Immuno Assay b) Immunochromatography (lateral flow) c) Immuno-concentration (flow through)	The tender specification currently permits both Immuno-concentration and Immunochromatography principles. During the pre-bid meeting, it was indicated that the Immunochromatography principle may be removed. We request that Immunochromatography be retained, considering the following technical and commercial advantages: 1. Earlier detection: Immunochromatography-based assays are commonly designed as 3rd-generation antibody assays capable of detecting IgM, IgG and, where applicable, IgA antibodies, whereas many immune-concentration assays are based on IgG detection. This can support detection during an earlier phase of infection. 2. Whole blood compatibility: Immunochromatography can support whole blood, serum and plasma samples, enabling finger-prick sampling and direct testing. Immuno-concentration generally requires serum/plasma preparation,	**Clarified as:** Refer Corrigendum-1.

CENTRAL MEDICAL SERVICES SOCIETY
Vishwa Yuvak Kendra, Chanakyapuri New Delhi - 21
MoHFW, Govt. of India

			making it less suitable for field-based testing. 3. Storage and transportation: Immunochromatography kits generally use dry, stabilized conjugates and can be designed for room-temperature storage and transportation, providing logistical advantages over assays requiring refrigerated storage. 4. Ease of use: Immunochromatography is generally designed as a simple, single-step testing procedure, whereas immuno-concentration methods may involve multiple processing steps. 5. Cost-effectiveness: Immunochromatography-based kits are generally more economical, making them suitable for large-scale screening and field-level implementation. In view of the above technical, operational and commercial advantages, we request that the Immunochromatography principle be retained in the tender specification to ensure wider participation and suitability for field-based diagnostic applications.	

Note: The above changes shall form part of the tender document.

19/10/26

(Manish Kumar Bhaskar)
Joint Director (Procurement)

मनीष कुमार भास्कर/Manish Kumar Bhaskar
संयुक्त निदेशक (प्रापण) / Joint Director (Procurement)
केन्द्रीय चिकित्सा सेवा सोसाइटी / Central Medical Services Society
स्वास्थ्य और परिवार कल्याण मंत्रालय / Ministry of Health and Family Welfare
भारत सरकार / Government of India